Pharmacokinetics and Biodistribution of a Nucleotide-Based Thrombin Inhibitor in Rats
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Purpose. To characterize the pharmacokinetic and tissue distribution profiles of a nucleotide-based thrombin inhibitor (GS522, phosphodiester oligonucleotide, GGTTGGTGTGGTTGG) following intravenous administration to rats.
Methods. Pharmacokinetic study: 10 mg/kg, 20 mg/kg, 30 mg/kg (6 animals/dose) were administered to rats by rapid injection into the femoral vein. Blood samples were collected over a 45 minute period. Plasma concentrations of GS522 were determined using capillary gel electrophoresis with laser-induced fluorescence detection. Biodistribution Study: l0mg/kg (400μl, 31.46 μCi/ml) of 3H-GS522 was administered to rats by rapid injection into the femoral vein. The animals were sacrificed by decapitation at 1, 5, 10, 30, 60, 360 minutes post-dose (3 rats/point). Brain, blood, duodenum, eyes, heart, kidney, liver, lungs, muscle, pancreas, skin, spleen and vein samples were collected, processed and quantitated using liquid scintillation counting.
Results. The pharmacokinetic profile declines in multiexponential manner, exhibiting extremely fast distribution and elimination (t1/2 = 7.6−9.0 min, Cl = 22.0−28.0 ml/min, V = 83.9−132.4 ml/kg). GS522 follows linear pharmacokinetics, with the area under the curve being proportional to the dose (Rsq = 0.9744). Highest radioactivity levels were detected in kidney, liver and blood (39.7, 15.7 and 15.3% dose/ respective organ). Less than 1% of the dose was detected in the heart, spleen and lungs, and >0.3% of the dose was found in the brain and eyes. The oligonucleotide associated radioactivity was uniformly distributed between the brain regions (left and right lobe and cerebellum). Six hours following the dose administration a statistically significant increase (p < 0.05) in radioactivity levels was observed in the brain, eyes, skin, liver, pancreas and vein.
Conclusions. The pharmacokinetic and biodistribution profiles of GS522 following intravenous administration to rats at three doses were characterized. The oligonucleotide associated radioactivity was widely distributed in tissues. The amount of radioactivity sharply decreased with time in most tissues. Kidney, liver and muscle were the main sites of accumulation. The oligonucleotide associated radioactivity did not cross the blood brain barrier to an appreciable extent. In addition, a statistically significant increase (p < 0.05) in the radioactivity levels observed in select tissues suggested a re-uptake mechanism for intact oligonucleotide or its degradation products.
- L. C. Griffin, G. F. Tidmarsh, L. C. Bock, J. J. Toole, and L. L. K. Leung. In vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits. Blood 81:3271 (1993).
- W.-X. Li, A. V. Kaplan, G. W. Grant, J. J. Toole, and L. K. Leug. A Novel Nucleotide-Based Thrombin Inhibitor Inhibits Clot-Bound Thrombin and Reduces Arterial Platelet Thrombus Formation. Blood 83:677 (1994).
- A. DeAnda, S. E. Coutre, M. R. Moon, C. N. Vial, L. C. Griffin, V. S. Law, M. Komeda, L. L. K. Leung, and D. C. Miler. Pilot Study of the Efficacy of a Thrombin Inhibitor for Use During Cardiopulmonary Bypass. Ann. Thorac. Surg. 58:344 (1994).
- W. A. Lee, J. A. Fishback, J-P. Shaw, L. C. Bock, L. C. Griffin, and K. C. Cundy. A Novel Oligonucleotide Inhibitor of Thrombin. II Pharmacokinetics in the Cynomolgus Monkey. Pharm. Res. 12:1943 (1995).
- M. J. Graham, S. M. Freier, R. M. Crooke, D. J. Ecker, R. N. Maslova, and E. A. Lesnik. Tritium Labeling of Antisense Oligonucleotides by Exchange with Tritiated Water. Nucl. Acids Res. 21:3737 (1993).
- L. Reyderman and S. Stavchansky. Quantitative Determination of Short Single-stranded Oligonucleotides From Blood Plasma Using Capillary Electrophoresis With Laser Induced Fluorescence. Anal. Chem., in print (1997).
- R. Zhang, R. P. Iyer, D. Yu, W. Tan, X. Zhang, Z. Lu, H. Zhqo, and S. Agrawal. Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration. J. Pharm. Exp. Ther. 278:971 (1996).
- P. S. Eder, R. J. DeVine, J. M. Dagle, and J. A. Walder. Substrate Specificity and Kinetics of Degradation of Antisense Oligonucleotides by a 3'Exonuclease in Plasma. Antisense Res. Develop. 1:141 (1991).
- J.-P. Shaw, J. A. Fishback, K. C. Cundy, and W. A. Lee. A Novel Oligonucleotide Inhibitor of Thrombin. I. In Vitro Metabolic Stability in Plasma and Serum. Pharm. Res. 12:1937 (1995).
- P. C. de Smidt, T. L. Doan, S. de Falco, and T. J. C. van Berkel. Association of Antsense Oligonucleotides with Lipoproteins Prolongs the Plasma Half-life and Modifies the Tissue Distribution. Nucl. Acids. Res. 19:4695 (1991).
- G. Goodarzi, M. Watabe, and K. Watabe. Organ Distribution and Stability of Phosphorothioated Oligodeoxyribonucleotides in Mice. Biopharm. Drug Disp. 13:221 (1992).
- S. Agrawal, J. Temsamani, and J. Y. Tang. Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice. Proc. Natl. Acad. Sci. USA 88:7595 (1991).
- P. A. Cossum, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S. R. Owens, P. M. Markman, J. P. Shea, and S. Crooke. Disposition of the 14C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intravenous Administration to Rats. J. Pharmacol. Exp. Ther. 267:1181 (1993).
- H. Sands, L. J. Gorey-Feret, A. J. Cocuzza, F. W. Hobbs, D. Chidester, and G. L. Trainor. Biodistribution and Metabolism of Internally 3H-Labelled Oligonucleotides.I.Comparison of a Phosphodiester and a Phosphorothioate. Mol. Pharmacol. 45:932 (1994).
- H. Sands, J. Gorey-Feret, S. P. Ho, Y. Bao, A. J. Cocuzza, D. Chidester, and F. W. Hobbs. Biodistribution and Metabolism of Internally 3H-Labelled Oligonucleotides. II. 3′,5′-Blocked Oligonucleotides. Mol. Pharmacol. 47:636 (1995).
- H. J. Gaus, S. R. Owens, M. Winniman, S. Cooper, and L. Cummins. On-Line Electrospray Mass Spectrometry of Phosphorothioate Oligonucleotide Metabolites. Anal. Chem. 69:313 (1996).
- P. A. Cossum, L. Truong, S. R. Owens, P. M. Markman, J. P. Shea, and S. Crooke. Pharmacokinetics of a 14C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats. J. Pharmacol. Exp. Ther. 267:1181 (1993).
- J. Rappaport, B. Hanss, J. B. Kopp, T. D. Copeland, L. A. Bruggeman, T. M. Coffman, and P. E. Klotman. Transport of Phosphorothioate Oligonucleotides in Kidney: Implications for Molecular Therapy. Kid. Int. 47:1462 (1995).
- R. Oberbauer, G. F. Schreiner, and T. W. Meyer. Renal Uptake of an 18-mer Phosphorothioate Oligonucleotide. Kid. Int. 48:1226 (1995).
- Pharmacokinetics and Biodistribution of a Nucleotide-Based Thrombin Inhibitor in Rats
Volume 15, Issue 6 , pp 904-910
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- Industry Sectors